Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Cancer incidence has risen, with improved survival due to advanced therapies like molecular targeted therapy.
• Molecular targeted therapy, while effective, is associated with significant cardiovascular toxicities.
• Cardiopulmonary function is critical for patient quality of life, necessitating careful management during cancer treatment.

Purpose of the Study:

• To review the cardiovascular toxicities associated with molecular targeted therapy.
• To highlight the importance of collaborative care between oncologists and cardiologists.
• To focus on the cardiac structural, electrophysiological, and vascular effects of targeted therapies.

Main Methods:

• Literature review of studies on cardiovascular toxicity induced by molecular targeted therapy.
• Analysis of adverse cardiovascular events, including left ventricular dysfunction, arrhythmias, and ischemia.
• Synthesis of current understanding of molecular targeted therapy's impact on cardiovascular health.

Main Results:

• Molecular targeted therapy can lead to serious cardiovascular side effects such as heart failure, hypertension, and thromboembolism.
• Previous research predominantly focused on chemotherapy-induced cardiotoxicity, with less emphasis on targeted agents.
• Understanding these toxicities is vital for proactive patient management.

Conclusions:

• Cardiovascular toxicity is a significant concern with molecular targeted therapy.
• Integrated care models involving oncologists and cardiologists are essential for managing these risks.
• Ongoing research and monitoring are needed to optimize patient outcomes and quality of life.